DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo

PAUSHAKLTD vs SUDARSHAN: Stock Comparison

PAUSHAK vs SUDARSHAN PHARMA INDUpdated 13 Nov 26, 4:08 PM ISTNSE & company filings

PAUSHAK shows a higher dividend yield and a higher net margin, while SUDARSHAN PHARMA IND shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

PAUSHAKLTD leads 4; SUDARSHAN leads 3 of 9

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

PAUSHAKLTDSUDARSHAN

Valuation lens

What price are you paying?

Market CapContext only
₹1,482 Cr
₹0 Cr
P/E RatioSUDARSHAN has the lower reading
31.33x
28.27x ✓
P/B RatioPAUSHAKLTD has the lower reading
2.87x ✓
4.11x
EPSPAUSHAKLTD has the higher reading
₹5.48 ✓
₹0.32
Book ValueContext only
₹199.18
₹6.14
Dividend YieldPAUSHAKLTD has the higher reading
0.42% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

P/E Ratio
SUDARSHAN has a lower P/E
28.27x vs 31.33x
P/B Ratio
PAUSHAKLTD has a lower P/B
2.87x vs 4.11x
EPS
PAUSHAKLTD has higher earnings per share
₹5.48 vs ₹0.32
Dividend Yield
PAUSHAKLTD has a higher dividend yield
0.42% vs 0%
Qtr Sales Growth
SUDARSHAN has stronger quarterly sales growth
24.4% vs 6.91%
Qtr Profit Growth
SUDARSHAN has stronger quarterly profit growth
38.7% vs -10.52%
Net Margin
PAUSHAKLTD has a higher net margin
17.99% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricPAUSHAKLTDSUDARSHAN
Live Price₹598.5₹32.71
Day Change-0.65%0.03%
Volume16,85592,985
52-Week High₹881.95₹39.3
52-Week Low₹342.5₹31.01
Distance from 52W High-32.14%-16.77%

Valuation

MetricPAUSHAKLTDSUDARSHAN
Market Cap₹1,482 Cr₹0 Cr
P/E Ratio31.33x28.27x
P/B Ratio2.87x4.11x
EPS₹5.48₹0.32
Book Value₹199.18₹6.14
Dividend Yield0.42%0%

Growth

MetricPAUSHAKLTDSUDARSHAN
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth6.91%24.4%
Qtr Profit Growth-10.52%38.7%

Profitability & Leverage

MetricPAUSHAKLTDSUDARSHAN
ROE8.01%—
ROCE7.08%—
Net Margin17.99%0%
Operating Margin23.57%—
Debt to Equity0.16x—

Shareholding

As of Sep 2026 • change vs previous quarter
MetricPAUSHAKLTDSUDARSHAN
Promoter Holding66.44%57.81%▼ 1.12 pp
FII Holding0.11%▲ 0.11 pp21.95%▲ 2.57 pp
DII Holding0.27%▲ 0.2 pp0%
Public Holding32.34%▼ 0.31 pp20.19%▼ 1.45 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: PAUSHAK and SUDARSHAN PHARMA IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.